Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.
about
Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomesMultiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease.Liver fat volume fraction quantification with fat and water T1 and T 2* estimation and accounting for NMR multiple components in patients with chronic liver disease at 1.5 and 3.0 T.Processes to manage analyses and publications in a phase III multicenter randomized clinical trialHepcidin and the iron enigma in HCV infection.Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy.Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trialHydrogen-1 MR spectroscopy for measurement and diagnosis of hepatic steatosisCorrelation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLDAssociation of γ-glutamyl transferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV).Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus.SRM targeted proteomics in search for biomarkers of HCV-induced progression of fibrosis to cirrhosis in HALT-C patients.Increased sialylation of site specific O-glycoforms of hemopexin in liver disease.Histopathological evaluation of fatty and alcoholic liver diseases.Quantification of liver fat with magnetic resonance imaging.Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: still important in the era of direct acting antiviral therapy?Statin therapy and serum transaminases among a cohort of HCV-infected veterans.HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis.Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause?The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients.Quantification of Liver Fat with mDIXON Magnetic Resonance Imaging, Comparison with the Computed Tomography and the Biopsy.
P2860
Q28081216-67B2763D-860E-4C29-A4D5-5BF1B3C23648Q30389327-40DD9D6C-775A-4A52-9BC1-6C9523FA989EQ30616960-CC478679-D30D-47DE-8B5A-EB0394DC0886Q33694159-93337359-37B1-49AC-B356-F977D84A27A0Q33779089-9011E856-B4A7-4DA5-84A6-EF47595FD2DDQ34021973-049B1CD9-78D5-485C-AEB3-05A839276D4FQ35142681-FF356D72-EE85-4BD2-BAD0-655F7EFC2C64Q36174863-BA98C031-5B8A-46B4-B9F3-3F2ADEFB3D12Q36219404-6022DD3F-7456-4358-9F4E-FC34DD1E7588Q36759370-10AFCEE7-4A4C-4135-8CB3-5DEA7A945445Q37016775-86054A1F-7673-4AC6-AE8A-8C6C118880A4Q37155233-4EAD3866-DB16-4A82-A663-A7F0E39D2283Q37278723-FFA7D781-2566-4DBB-85C4-D32263DEEC98Q37811072-8FD0CD94-DB47-4274-A20D-DC1A18A0ED6AQ37811338-9B3AEDF5-1C4C-4CB7-83FF-D4398F26A408Q38170504-9279E247-7FA9-40DA-88A5-5BE14BE4F3D1Q41345786-95902C39-8B42-4CE0-BC6B-D3042E5283AAQ43040452-4FCB5D26-C43F-496F-A0D3-E6F2C9AC1E8FQ43671252-E549CF99-6446-4519-ABE9-B8EA97E9BE81Q48256212-62605662-F4FD-4ACF-8001-FC5AA9D64646Q50150871-921CAC13-3156-4860-9CEC-04C3D1720037
P2860
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Evolution of hepatic steatosis ...... inst cirrhosis (HALT-C) trial.
@en
Evolution of hepatic steatosis ...... rm treatment against cirrhosis
@nl
type
label
Evolution of hepatic steatosis ...... inst cirrhosis (HALT-C) trial.
@en
Evolution of hepatic steatosis ...... rm treatment against cirrhosis
@nl
prefLabel
Evolution of hepatic steatosis ...... inst cirrhosis (HALT-C) trial.
@en
Evolution of hepatic steatosis ...... rm treatment against cirrhosis
@nl
P2093
P2860
P356
P1433
P1476
Evolution of hepatic steatosis ...... inst cirrhosis (HALT-C) trial.
@en
P2093
Anna S Lok
Chihiro Morishima
Gregory T Everson
HALT-C Trial Group
Hae-Young Kim
Herbert L Bonkovsky
James E Everhart
Joel K Greenson
John C Hoefs
Karen L Lindsay
P2860
P304
P356
10.1002/HEP.22865
P407
P577
2009-06-01T00:00:00Z